2,938 Shares in Charles River Laboratories International, Inc. (NYSE:CRL) Bought by Qtron Investments LLC

Qtron Investments LLC purchased a new stake in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 2,938 shares of the medical research company's stock, valued at approximately $542,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Norges Bank bought a new stake in shares of Charles River Laboratories International in the fourth quarter valued at $98,886,000. Wellington Management Group LLP boosted its holdings in shares of Charles River Laboratories International by 9.0% in the 4th quarter. Wellington Management Group LLP now owns 4,076,426 shares of the medical research company's stock worth $752,508,000 after purchasing an additional 335,658 shares in the last quarter. Raymond James Financial Inc. purchased a new position in shares of Charles River Laboratories International during the fourth quarter worth approximately $42,776,000. Invesco Ltd. raised its position in Charles River Laboratories International by 17.1% in the 4th quarter. Invesco Ltd. now owns 1,034,180 shares of the medical research company's stock worth $190,910,000 after purchasing an additional 151,159 shares during the period. Finally, Cooke & Bieler LP increased its holdings in shares of Charles River Laboratories International by 42.1% in the fourth quarter. Cooke & Bieler LP now owns 426,767 shares of the medical research company's stock worth $78,781,000 after buying an additional 126,372 shares during the period. 98.91% of the stock is owned by institutional investors.

Charles River Laboratories International Stock Up 1.6 %

Shares of NYSE CRL traded up $1.64 during midday trading on Friday, hitting $105.89. The company's stock had a trading volume of 1,658,424 shares, compared to its average volume of 891,257. The firm has a market capitalization of $5.20 billion, a price-to-earnings ratio of 705.91, a price-to-earnings-growth ratio of 4.54 and a beta of 1.45. Charles River Laboratories International, Inc. has a 1 year low of $91.86 and a 1 year high of $254.15. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.41 and a quick ratio of 1.14. The business's fifty day simple moving average is $152.05 and its two-hundred day simple moving average is $174.61.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its quarterly earnings data on Wednesday, February 19th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.50 by $0.16. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The business had revenue of $1 billion for the quarter, compared to analysts' expectations of $983.63 million. During the same period last year, the firm earned $2.46 earnings per share. The company's revenue for the quarter was down 1.1% compared to the same quarter last year. On average, equities analysts predict that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Insider Buying and Selling

In related news, EVP Joseph W. Laplume sold 4,400 shares of the company's stock in a transaction that occurred on Thursday, February 20th. The stock was sold at an average price of $162.50, for a total value of $715,000.00. Following the completion of the transaction, the executive vice president now directly owns 20,013 shares of the company's stock, valued at $3,252,112.50. This represents a 18.02 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, COO Birgit Girshick acquired 1,514 shares of Charles River Laboratories International stock in a transaction dated Thursday, February 20th. The shares were bought at an average price of $164.63 per share, with a total value of $249,249.82. Following the transaction, the chief operating officer now directly owns 55,058 shares in the company, valued at approximately $9,064,198.54. The trade was a 2.83 % increase in their position. The disclosure for this purchase can be found here. 1.30% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the stock. Robert W. Baird lowered their price target on shares of Charles River Laboratories International from $177.00 to $173.00 and set a "neutral" rating for the company in a report on Thursday, February 20th. The Goldman Sachs Group lowered shares of Charles River Laboratories International from a "buy" rating to a "neutral" rating and reduced their price objective for the company from $190.00 to $170.00 in a research note on Friday, March 21st. Citigroup raised Charles River Laboratories International from a "sell" rating to a "neutral" rating and lifted their price objective for the stock from $155.00 to $175.00 in a report on Tuesday, March 4th. Barclays decreased their target price on Charles River Laboratories International from $160.00 to $145.00 and set an "equal weight" rating on the stock in a report on Thursday, April 10th. Finally, William Blair downgraded shares of Charles River Laboratories International from an "outperform" rating to a "market perform" rating in a report on Wednesday, January 22nd. One analyst has rated the stock with a sell rating and sixteen have issued a hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $182.00.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).